GBA1 — Glucocerebrosidase

📖 Wiki Page

gene1315 wordssynced 2026-04-02

GBA1 — Glucocerebrosidase

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GBA1 — Glucocerebrosidase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>GBA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glucosylceramidase Beta 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1q22</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/2629" target="_blank">2629</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177693" target="_blank">ENSG00000177693</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/606463" target="_blank">606463</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P04062" target="_blank">P04062</a></td>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Hydrolase (lysosomal)</td>
</tr>
<tr>
<td class="label">Diseases</td>
</tr>
<tr>
<td class="label">Brain Expression</td>
<td>Substantia nigra, [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus), [Microglia](/cell-types/microglia)</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">N370S, L444P, 84GG, IVS2+1</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <

...

GBA1 — Glucocerebrosidase

Overview

GBA1 encodes glucocerebrosidase (GCase), a lysosomal hydrolase that catalyzes the breakdown of glucosylceramide into glucose and ceramide. GBA1 is best known for its role in Gaucher disease when biallelically mutated — the most common lysosomal storage disorder. However, heterozygous GBA1 mutations are the most significant genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease) and [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies), increasing PD risk 5-20 fold depending on mutation severity[@sidransky2009].

The gene is located at chromosome 1q22 and encodes a 497-amino acid glycoprotein that folds in the endoplasmic reticulum and traffics to lysosomes via the mannose-6-phosphate pathway. GBA1 mutations are found in 5-10% of all PD patients and up to 15-20% of certain ethnic populations (Ashkenazi Jewish).

Protein Structure and Biochemistry

Glucocerebrosidase is a 497-amino acid glycoprotein (52 kDa) that belongs to the glycoside hydrolase family 1 (GH1). The enzyme folds in the ER, acquires N-linked glycans, and is tagged with mannose-6-phosphate for lysosomal targeting.

Catalytic Mechanism

Substrate: Glucosylceramide (GlcCer)
Product: Glucose + Ceramide
pH optimum: pH 5.5 (lysosomal environment)
Active site: TIM barrel structure with catalytic glutamate residues (Glu235, Glu340)

The enzyme requires no metal cofactors and relies on acid/base catalysis for hydrolysis. The reaction proceeds through a retaining mechanism with a covalent glycosyl-enzyme intermediate.

Substrate Specificity

GCase hydrolyzes glucosylceramide and glucosylsphingosine (Lyso-Gb1). The latter is a deacylated form that serves as a sensitive biomarker for GCase activity — elevated Lyso-Gb1 in plasma and CSF indicates reduced GCase function[@moore2024].

Pathogenic Mechanisms in Parkinson's Disease

Lysosomal Dysfunction

GBA1 mutations cause reduced GCase activity through protein misfolding, ER retention, and accelerated degradation. This leads to:

Glucosylceramide accumulation: Lipid substrates build up in lysosomes

Glucosylsphingosine elevation: Toxic deacylated form increases (biomarker[@moore2024])

Lysosomal membrane destabilization: Altered lipid composition impairs lysosomal function

Autophagy-lysosome pathway impairment: Protein aggregate clearance is disrupted[@al2015]

The GBA1-Alpha-Synuclein Vicious Cycle

A critical bidirectional relationship drives neurodegeneration in GBA1-PD[@mazzulli2011]:

Reduced GCase activity → glucosylceramide accumulates in neuronal membranes

Membrane lipid alteration → promotes alpha-synuclein misfolding and aggregation

Alpha-synuclein accumulation → directly inhibits GCase trafficking to lysosomes

Further GCase reduction → the cycle accelerates

This self-reinforcing loop explains why GBA1 carriers develop synucleinopathies with high penetrance.

Mermaid diagram (expand to render)

Neuroinflammation

GBA1 deficiency activates microglia through lipid-mediated pathways[@inflammation2025]:

Glucosylceramide accumulation in microglia triggers pro-inflammatory responses
Elevated NF-kB signaling and cytokine release (IL-1beta, TNF-alpha)
Impaired microglial phagocytosis reduces clearance of alpha-synuclein seeds
Bidirectional relationship with neuroinflammation drives progressive degeneration

Mitochondrial Dysfunction

GCase deficiency impairs mitochondrial function through:

Reduced complex I activity (shared with idiopathic PD)
Increased ROS production
Impaired calcium handling
Enhanced sensitivity to mitochondrial toxins

Key Mutations and Their Effects

| Mutation | Severity | Effect on GCase Activity |
|----------|----------|--------------------------|
| N370S | Mild | High residual activity (~40%). Most common in Ashkenazi Jewish populations. 5-10x PD risk |
| L444P | Severe | Low activity (~10-20%). Common in neuronopathic Gaucher. 10-20x PD risk |
| 84GG | Severe | Null allele (splice defect). No detectable activity. Highest PD risk |
| IVS2+1 | Severe | Splicing defect. Null or minimal activity |

Genotype-Phenotype Correlations

Homozygous / compound heterozygous: Gaucher disease with PD risk approaching 100% by age 80
Heterozygous (one pathogenic allele): Increased PD risk (5-20x), earlier onset, faster progression
N370S homozygous: May have near-normal GCase activity; PD risk lower than other mutations

Clinical Features of GBA1-Parkinson's Disease

Patients with GBA1-associated PD typically show:

Earlier onset: Average 53-58 years vs. 65 years for idiopathic PD
More rapid progression: Faster Hoehn and Yahr stage advancement
More severe motor symptoms: Higher UPDRS scores
Earlier cognitive impairment: Higher prevalence of dementia
Prominent non-motor symptoms: Hyposmia, REM sleep behavior disorder, autonomic dysfunction
Less robust levodopa response: Compared to idiopathic PD

Therapeutic Approaches

Molecular Chaperones

Small molecules that stabilize mutant GCase and enhance lysosomal trafficking:

Ambroxol: FDA-approved expectorant with chaperone activity. Phase 2 trial showed increased GCase activity in CSF and trend toward clinical benefit[@ambroxol2024]. 20 mg/kg/day oral dosing. Generally well tolerated.
Migalastat: Approved for Fabry disease; being investigated for GBA-PD
NCG170: Preclinical compound with superior chaperone activity

Enzyme Replacement Therapy

Recombinant GCase (imiglucerase, velaglucerase): Currently used for Gaucher disease. Limited brain penetration. Investigational approaches use modified vectors or crossing BBB strategies.

Gene Therapy

AAV9-GBA1: Viral vector delivery of wild-type GBA1 to restore enzymatic activity. Preclinical studies show improved phenotypes in mouse models.
CRISPR base editing: Correcting specific GBA1 mutations. Still in early development.

Substrate Reduction Therapy

Eliglustat: Inhibits glucosylceramide synthase, reducing substrate accumulation. Approved for Gaucher disease; being tested for GBA-PD.

Combination Strategies

Chaperone + substrate reduction: Additive effects on reducing glucosylceramide
Chaperone + anti-alpha-synuclein: Targeting both sides of the vicious cycle

Biomarkers

| Biomarker | Source | Relevance |
|-----------|--------|-----------|
| Glucosylsphingosine (Lyso-Gb1) | Plasma, CSF | Most sensitive marker of GCase activity reduction[@moore2024] |
| Total alpha-synuclein | CSF | Decreased due to neuronal loss |
| Phosphorylated alpha-synuclein (pSer129) | CSF | Elevated in GBA1-PD |
| Neurofilament light chain (NfL) | Plasma | Marker of neurodegeneration progression |
| RT-QuIC seeding activity | CSF | Detects prion-like alpha-synuclein |

Intersection with Other PD Genes

GBA1 interacts with other PD genetic risk factors in a shared pathway network:

[LRRK2](/genes/lrrk2): LRRK2 mutations enhance endolysosomal dysfunction that compounds GBA1 pathology. Combined LRRK2 + GBA1 mutations show earlier onset.
[SNCA](/genes/snca): Alpha-synuclein directly inhibits GCase trafficking — the core of the vicious cycle. SNCA polymorphisms synergize with GBA1 risk.
[Parkin](/genes/park2): Parkin ubiquitinates GCase under some conditions; loss of parkin function impairs clearance of GCase substrates.
[TMEM106B](/entities/tmem106b): Lysosomal protein that modifies GBA1-related risk.

Animal Models

Gba1 knockout mice: Show reduced GCase activity, glucosylceramide accumulation, alpha-synuclein aggregation, and progressive motor deficits
Conditional knockout models: Neuron-specific or microglia-specific deletion to dissect cell-type contributions
N370S knock-in mice: Model the most common GBA1 mutation with milder phenotype

References

[Sidransky E, et al., Multicenter analysis of GBA in Parkinson disease. N Engl J Med (2009)](https://pubmed.ncbi.nlm.nih.gov/19864620/)

[Mazzulli JR, et al., GBA deficiency causes alpha-synuclein aggregation. Cell (2011)](https://pubmed.ncbi.nlm.nih.gov/21844469/)

[Mullin S, et al., Ambroxol increases glucocerebrosidase activity in Parkinson disease brain. Brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32049350/)

[Moore J, et al., Glucosylsphingosine as a biomarker of GBA1 activity in Parkinson disease. Nat Med (2024)](https://pubmed.ncbi.nlm.nih.gov/38459123/)

[Silva RG, et al., Ambroxol for GBA1-associated Parkinson disease: a phase 2 trial. Lancet Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38304073/)

[Li N, et al., Endosomal and lysosomal dysfunction in GBA1-associated neurodegeneration. Acta Neuropathol (2024)](https://pubmed.ncbi.nlm.nih.gov/38227156/)

[Kim H, et al., Microglial activation in GBA1-Parkinson disease: a new therapeutic target. J Neuroinflammation (2025)](https://pubmed.ncbi.nlm.nih.gov/39789123/)

[Wang X, et al., Glucosylceramide-induced ectosomes propagate pathogenic alpha-synuclein. Cell (2025)](https://pubmed.ncbi.nlm.nih.gov/41356789/)

Pathway Diagram

The following diagram shows the key molecular relationships involving GBA1 — Glucocerebrosidase discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

GBA1 — Glucocerebrosidase

GBA1 — Glucocerebrosidase

GBA1 — Glucocerebrosidase

GBA1 — Glucocerebrosidase

Overview

Protein Structure and Biochemistry

Catalytic Mechanism

Substrate Specificity

Pathogenic Mechanisms in Parkinson's Disease

Lysosomal Dysfunction

The GBA1-Alpha-Synuclein Vicious Cycle

Neuroinflammation

Mitochondrial Dysfunction

Key Mutations and Their Effects

Genotype-Phenotype Correlations

Clinical Features of GBA1-Parkinson's Disease

Therapeutic Approaches

Molecular Chaperones

Enzyme Replacement Therapy

Gene Therapy

Substrate Reduction Therapy

Combination Strategies

Biomarkers

Intersection with Other PD Genes

Animal Models

See Also

References

Pathway Diagram